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While some progress has been made lately in developing transplantation therapy against 
acute myeloid leukemia (AML), it remains a problematic and aggressive disease, associated 
with both poor survival, as well as treatments with high toxicity. The field of nanomedicine is 
however aiming to improve treatment therapies by using dedicated nanocarriers to deliver 
therapeutics. Such drug delivery systems may provide benefits like more targeted drug 
delivery, as well as reduced side effects. Nanocarriers also open up for the repurposing of 
old drugs for new targets, as well as tools to deliver drug with poor pharmacokinetic 
properties. 
 
This project dealt with the production, characterization, and in vitro experimentation of 
liposomal and PLGA-based nanocarriers, with the aim of determining whether or not they 
were suitable to carry drugs directed against AML cells. The present study investigated the 
size and morphology of nanoparticles, ability to carry drugs, internalization into AML cells, 
and cytotoxic properties. In addition, the possibility to deliver siRNA into AML cells was 
explored. Liposomes and polymeric PLGA nanoparticles were studied as drug delivery 
systems. 
 
Both DLS and TEM characterization showed favorable results for both liposomes and PLGA 
nanoparticles, both being under 400 nm and thus viable for traveling through the blood 
stream. Internalization of nanocarriers into AML cells was also successfully demonstrated. 
AML cells had a high endocytic capacity for liposomes and PLGA nanoparticles. Liposome 
internalization could not be dampened by inhibitors of clathrin- or caveolin-mediated 
endocytosis. Drug loading experiments showed that PLGA had acceptable capacity to carry 
chlorpromazine, with a limited release of the drug during 72 hours. A peptide based drug 
was sought loaded into liposomes, but with a very limited encapsulation efficiency. The 
success in drug loading was also evident in the cytotoxicity experiments, where CPZ-loaded 
PLGA nanoparticles demonstrated to have a clear apoptotic effect on AML cells equivalent to 
that of free drug, while no conclusive data was obtained from liposomal delivery of NAT-
inhibitor peptide. Attempts were made at using liposomes for more advanced targeting 
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therapy with siRNA and RNAi-based therapy, and though some potential was seen, no effect 
from siRNA was demonstrated when used with produced cationic liposomes. 
 
The data in this study demonstrates that nano-based drug delivery systems have potential 
for anti-AML therapy, and can accelerate the development of novel therapies, both using 





2.1 - Acute myeloid leukemia 
Leukemia is a collective term for a heterogeneous group of diseases characterized by the 
malignant clonal proliferation of blood progenitor cells. This occurs in the bone marrow 
(BM), the site of blood cell production (hematopoiesis), where they develop, accumulate and 
expand before spreading to the entire body via the blood circulation. The uncontrolled 
proliferation within the BM results in the replacement of normal blood cells with abnormal 
leukemic cells, causing a reduction in the numbers of normal red blood cells, platelets, and 
leukocytes. This in turn results in a range of systemic symptoms such as anemia, bleeding, 
and increased risk of life-threatening infection [1]. Leukemia is classified as either acute or 
chronic, based on the disease onset and course, as well as either myeloid or lymphoid, based 
on the malignant progenitor cell of origin. For example, acute myeloid leukemia (AML), 
which is the focus of this work, is acute and thus is characterized as usually having a rapid 
course and being fatal within weeks or months if left untreated. Chronic leukemias, 
however, develops later in the differentiation process, and as a result it takes years or even 
decades for symptoms to occur. AML develops from immature myeloid cells, which gives rise 
to red blood cells, platelet-producing megakaryocytes, and myelocytic white blood cells. As 
with most cancers, AML is a heterogeneous disease, and as such, vary in differentiation, 
genetic aberrations, response to treatment, and prognosis [1]. 
 
2.2 - AML treatment and challenges 
The primary method of treating AML is by chemotherapy, with the first phase being 
induction therapy, which has the goal of eradicating virtually all leukemia cells and achieve 
complete remission. This is usually done with the combination of two strong cytostatic drugs 
that target cancer cells [2]. The second phase is consolidation therapy, which lasts for weeks, 
and has the goal of removing any remaining, undetectable cells that may cause the leukemia 
to relapse [2]. Chemotherapy however, is an unspecific method of treatment, as it also 
affects healthy cells in the BM, making it necessary with isolation, antibiotic treatment and 
blood transfusion. The toxicity of the drug treatments results in potentially intolerable levels 
of side effects, which exclude especially older patients and patients with poor general health 
conditions [3]. An increase in age, as well as the presence of other diseases, contribute to 
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increasing the risk of mortalities from the consolidation therapy. Other risks and side effects 
of chemotherapy include fungal [4-6] and bacterial infections [7](both major causes of 
therapy-related leukocyte death), cardiotoxicity, mucositis, impaired liver functions, and 
incidents of veno-occlusive syndrome [8, 9]. 
 
While other therapies against AML do exist, such as allogeneic stem cell therapy, not all 
patients are eligible for it. This is due to the nature of the therapy and its requirements, one 
of which being the need of a matching donor. Not only that, AML patients suitable for stem 
cell therapy still require chemotherapy to control the disease, before the transplant to 
eradicate the remaining leukemia cells. 
 
Another challenge of cancer chemotherapy in general, is that some patients who have 
undergone chemotherapy alone or in combination with radiation, develop what is classified 
as “therapy-related” AML, which is the development of cancerous AML cell lines with 
resistance to chemotherapeutics, and is both difficult to treat and associated with high 
mortality [10-13]. 
 
What all these issues highlight, is the need for better methods of treatment that take into 
account AML patients with unfavorable biological variables, that overcome chemoresistance 
and improve tolerability, and that ensure that all cancer cells are eradicated/eliminated. 
Despite the therapeutic advances over the past two decades, the prognosis of patients with 
AML remains poor, especially among elderly patients, who make up the majority of AML 
patients [1, 3, 8]. Further research into alternative drug therapies and therapeutic methods 
for treating AML is therefore needed. Today, this research includes for example the 
development of better cytostatics and more targeted therapies. Much interest is also 
directed at the development of novel nanotechnology-based therapeutic formulations, 
which aim to overcome the problems of existing chemotherapeutic treatment methods. 
 
2.3 - Nanocarriers 
One focus of nanomedicine, i.e. the application of nanotechnology in medicine, is the design 
and development of nanoscale drug delivery systems called nanocarriers, which both carry 
and more specifically target therapeutics, either to specific sites in the body or to specific 
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cells. These NCs vary in size, composition, and function: They can for example be hollow 
containers, solid particles, or tightly packed polymer particles. Examples of nanocarriers are 
magnetic nanoparticles, gold nanoparticles, dendrimers, mesoporous silica nanospheres, 
carbon nanotubes, nanocolloids, polymeric nanoparticles, micelles, and liposomes. Some 
examples of nanocarrier platforms currently being tested in various stages of clinical trials 
against different types of cancer include: Cyclodextrin nanoparticles, PLGA polymer 
nanoparticles, polymeric micelles, and colloidal gold nanoparticles [14, 15], with many of 
them being liposomes and lipid-based products [16]. Their common feature is their 
nanoscale size, ranging between 1-1000 nm, their ability to carry small therapeutic 
molecules, and the possibility to functionalize the nanocarriers with additional molecules, 
ligands and probes. Because of these factors, the use of nanocarriers offers many 
advantages as a method of drug delivery. 
 
2.3.1 - Advantages of nanocarrier drug delivery systems 
One advantage presented by the use of nanocarrier formulations is the ability to 
load/encapsulate or bind drugs and therapeutic agents to nanocarriers. This is often 
accomplished with high packing efficiency, and thus high drug load, due to the large surface-
area-to-volume of the nanocarriers. Encapsulation also enables the use of insoluble drugs by 
stably incorporating them into hydrophobic microenvironments of nanocarriers. This opens 
up for the use of a group of drugs, both new and old, which would otherwise be considered 
ineffective due to their insolubility, or unviable due to their need for problematic organic 
solvents such as Cremophor EL® [17]. By encapsulating the drugs, nanocarriers also protect 
the drugs from being degraded or eliminated before reaching the target tissue or cell. 
Additionally, multiple drugs may be loaded onto the same nanocarrier, at certain ideal ratios 
if necessary, as is the case for the daunorubicin-cytarabine loaded liposomal formulation 
CPX-351, currently in clinical trials for treatment against AML [18, 19]. Not only does this 
open for better control of positive therapeutic synergy, but as with traditional drug delivery, 
using less of each drug results in less of the side effects from each of them. Drug loading also 
results in the drug behaving in vivo with the physico-chemical properties of the nanocarrier, 
which are more flexible in their ability to be chemically modified and functionalized with 
various molecular additions. 
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A commonly included nanocarrier surface modification is the hydrophilic polymer PEG 
(poly(ethylene glycol) [CH2CH2O]n). PEGylation coating is used to avoid detection and uptake 
by macrophages of the mononuclear phagocytic system (MPS) which clear out nanocarriers 
larger than 30 nm [20]. In addition to reducing clearance of the nanocarriers, this inclusion 
may also sterically stabilize the nanocarriers and prevent agglomeration, thus further 
improving bioavailability of the drug after intravenous administration. These factors 
contribute to making the nanocarriers more likely to survive in the blood stream and reach 
the target site and cells [15]. So as with encapsulation, PEGylation benefits the delivery of 
drugs by increasing the circulation time. This in turn results in a more sustained and 
controlled drug release, making it easier to maintain a systemic drug concentration within 
the therapeutic window, i.e. above the concentration needed for therapeutic effect, but 
below the concentration where toxic side effects start to occur [21]. 
 
Further improvement to the specificity of the nanocarrier-mediated drug delivery can be 
obtained by the inclusion of targeting ligands. Examples of ligands include specific 
antibodies, peptides, or molecules such as mannose or folate. Such ligands may target 
specific receptors found overexpressed on the surface of cancer cells [8, 15, 22]. They can be 
either conjugated to the surface of the nanocarrier, or to the ends of the PEG chains if 
present. This method of “active targeting” of the nanocarrier increases its concentration at 
the desired site and cells in the body, while also reducing non-specific targeting of drugs to 
normal cells. This not only aims to enhance the therapeutic efficacy of the formulation, but 
also to reduce its toxicity and side effects, as well as the amount of drug needed to get the 
desired effect. Not only does this lower the necessary drug dose needed for therapeutic 
effect, as more of the drug reaches the intended targets, it also raises the maximum non-
toxic drug dose, as less of it reaches unwanted sites to cause side effects. This further 
increases the therapeutic index and concentration window [21]. In addition to helping the 
nanocarriers reach the target cells, the inclusion of ligands may also increase cellular uptake 
and facilitating internalization of nanocarriers in cancer cells, again by targeting specific 
cancer markers for receptor-mediated endocytosis. 
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An important part of cancer therapy is diagnosing the cancer and determining the 
biodistribution of both the cancer and the therapeutic agents. As a result, many studies have 
focused on the development of multifunctional nanocarrier formulations that include both 
therapeutic and diagnostic imaging agents, and thus serve as what is called “theragnostic” 
platforms [14, 22]. Examples are the inclusion of fluorescent probes, quantum dots, and the 
use of contrast agents such as superparamagnetic iron oxide nanoparticles (SPIONs), either 
encapsulated in the nanocarrier, or as the nanocarrier itself. By including superparamagnetic 
iron oxide nanoparticles, the nanocarriers and thus the therapeutic drug as well as the target 
cell, can be tracked using non-invasive MRI imaging techniques [23, 24]. Doing this, the 
nanocarriers may serve diagnostic purposes as well as a therapeutic one, and by monitoring 
where the nanocarriers accumulate and release their drug load, therapeutic adjustments 
may be done even as the treatment is underway. This kind of treatment and biodistribution 
monitoring is also useful for nanotoxicological research of the nanocarriers. 
 
2.3.2 - Liposomal drug delivery systems 
One type of nanocarrier platform that has garnered much interest for targeted drug delivery 
are liposomes, which are defined as spherical vesicles made up of a bilayer membrane of 
either synthetic or natural phospholipids, that encloses an aqueous phase [25]. As liposomes 
possess both an aqueous interior and hydrophilic membrane domains of the lipid bilayer, it 
can store both hydrophobic and hydrophilic drug molecules, as well as imaging agents. They 
can vary in size and consist of one or more concentric lipid bilayers. Based on this they may 
be classified as: multilamellar large vesicles (MLV), large unilamellar vesicles (LUV), or small 
unilamellar vesicles (SUV) [20, 25]. Part of the interest in liposomes is also due to their 
components having desired biological properties such as biocompatibility, biodegradability 
and low immunogenicity, which are of importance both during and after drug delivery [14]. 
Liposomes are also flexible in membrane composition, making it possible to include a variety 
of different components such as ionic lipids to obtain a certain charge, cholesterol for 
increased membrane stability, and helper lipids to reduce cytotoxicity. As with other types of 
nanocarriers, liposomes provide many advantages due to the ability to modify the surface 
and functionality of the platform, and by conjugating various targeting and/or tracking 
ligands to the lipids included in the formulation. They also benefit from the inclusion of lipids 
conjugated with the PEG polymers, making what is called a “stealth liposome” [26]. This 
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addition not only helps with steric protection and stability, it also decreases blood plasma 
protein adsorption and hides the liposomes from the macrophages of the MPS, thus 
avoiding clearance and resulting in prolonged plasma half-life [25]. In addition to their 
attractive properties of liposomes, and clear potential for enhanced drug delivery, it should 
also be noted that FDA-approved liposome formulations carrying anti-cancer therapeutics no 
only exist, but are already in use [27]. 
 
2.3.3 - Polymer-based nanoparticle drug delivery systems 
A drug delivery platform that shows great promise is the polymer-based nanocarriers. These 
nanocarriers are made up of either organic or synthetic polymers, which in turn can be made 
up of either the same or different types of monomers. Copolymers are made up of at least 
two types of monomers, and the monomers can be arranged along the polymer chain either 
randomly, periodically, or in separate monomer-type-based blocks, to give a few examples. 
Different polymers and monomers can be combined, at specific ratios, resulting in polymer 
nanocarriers with properties of both polymer types. This makes PEG polymer a natural 
inclusion for copolymer nanocarriers so as to avoid opsonization and increase circulation 
time [28], and it also allows for amphiphilic block copolymers that consist of hydrophilic and 
hydrophobic polymer blocks, that self-assemble into micelles or vesicles, much like 
amphiphilic phospholipids [14]. Polymers are favored for often being biocompatible and 
biodegradable, which is beneficial as this avoids the potential adverse effects from 
prolonged exposure or accumulation, but also helps ensure drug release and effectiveness.  
 
Polymeric nanocarriers can be divided into groups based on the mechanism of drug 
incorporation, which depends on the polymeric composition. Amphiphilic block copolymers 
make up both polymeric micelles, that bind with drugs through hydrophobic interactions, as 
well as polymer capsules/vesicles or polymersomes, which encapsulate the drug within their 
oily or aqueous phase [14]. Loading can also be done by covalently binding the drug 
molecule to the polymer by simple ester or amide bonds, which can be hydrolyzed in vivo. 
Many polymeric nanocarriers are made up of a solid polymeric matrix, called nanospheres or 
polymer nanoparticles, inside which the drug molecule can intercalate through hydrophobic 
interactions. Polymers also support for functionalization and surface modification, with for 
example the potential covalent linkage of PEG-polymer as mentioned [28], or carbohydrate-
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binding ligands that facilitate cell targeting [29], or pH-sensitive or hypothermic polymers 
that intercalate into the nanoparticle matrix and open up for triggered release [30]. 
 
Many different types of polymers are being studied, and even tested in clinical trials, for use 
in drug delivery [31], including poly(amino acids) and proteins such as albumin, and 
polysaccharides like chitosan, cyclodextrin and dextrans [8, 32]. The most commonly used 
and widely researched are however the synthetic polyesters polylactide (PLA) [33], and 
poly(D,L-lactide-co-glycolide) (PLGA) [28]. PLGA as a drug-carrying nanoparticle has for 
example shown results of providing anticancer agents such as doxorubicin a more potent 
and longer lasting tumor suppression effect when conjugated to PLGA nanoparticles [34], 
and to paclitaxel an enhanced cytotoxic effect for tumor cells in vitro as well as a higher and 
prolonged drug concentration above effective value in vivo [35]. Due to its poor water 
solubility, paclitaxel use Cremophor EL®, an organic solvent associated with eliciting severe 
hypersensitive reactions. When loaded inside PLGA-PEG nanoparticles however, paclitaxel 
has been shown to induce similar levels of apoptotic cell death for HeLa cells and thus 
maintaining chemotherapeutic potency, but without any adverse effects from the solvent 
[17]. 
 
2.3.4 - Nanocarrier internalization 
After the production of nanocarriers, the encapsulation of therapeutics, and successful 
targeting of nanocarrier to target cells, an issue still remains, which is the internalization of 
drug-loaded nanocarriers into the cell cytoplasm and intracellular fate. Endocytosis, the 
active transport of molecules and particles across the cell membrane, can be divided into 
many categories. Phagocytosis, the engulfing and uptake of large particles, is one example, 
and is a process characteristic for dedicated phagocytes [36]. Another category is 
pinocytosis, defined as the uptake of fluids, solutes, and ligands, often via plasma membrane 
receptors. Pinocytosis is present in virtually all cells and has multiple forms, and can in turn 
be divided into the following categories: clathrin-mediated endocytosis (CME), caveolae-
mediated endocytosis (CvME), clathrin- and caveolae-independent endocytosis, and 
micropinocytosis [36, 37]. For the production of effective nanocarrier formulations able to 
mediate a biological response, the endocytic mechanisms for internalization need to be 
examined and understood, as they may differ depending on the particular nanocarrier, 
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nanocarrier size, and for the particular cell type for which they intended [38-40]. This can for 
example be done using chemical inhibitors targeted against pathway-specific mechanisms or 
proteins, and looking for an effect on uptake. 
 
2.4 - Repurposing of established drugs for cancer chemotherapy 
Nanocarriers may also serve a critical role in the practice of repurposing established drugs as 
an efficient way to develop new therapies, so as to avoid the usual amount of time and 
funding associated with the development and clinical testing of new drugs. This can be done 
for a range of diseases, and is common in cancer chemotherapy, where for instance 
thalidomide and analogs have shown to be effective against myeloid diseases [41]. Another 
example is chlorpromazine (CPZ), an anti-psychotic drug used against schizophrenia, but that 
has shown have a pro-apoptotic effect on AML cell lines [42, 43], and as a result potential as 
a chemotherapeutic agent against AML. However, as an anti-psychotic, CPZ affects the 
central nervous system (CNS), causing non-schizophrenic individuals to experience side 
effects such as drowsiness, dizziness, and extrapyramidal reactions (e.g. Parkinson-like 
symptoms, dystonia, akathisia, tardive dyskinesia)[44]. So if CPZ is to be used against AML, 
its effect on the CNS has to be diminished, and thus needs to be in a formulation which 
prevents it from crossing the blood-brain barrier (BBB). Encapsulating the CPZ inside 
nanocarriers would help achieve this as they would be too large to cross the barrier, and 
designed so to exhibit preferential accumulation at target sites by for example the inclusion 
of targeting-ligands, thus significantly reducing any CPZ-CNS interaction. 
 
2.5 - Targeted therapy using HSP90-inhibitors and siRNA 
Targeted therapy is a much researched and used treatment strategy wherein one employs 
drugs that are more selective and more precise in what they target and affect, compared to 
conventional chemotherapeutics. This method not only promises better results, but fewer 
side effects as well. One such example for the treatment of AML is the specific targeting of 
the heat shock protein 90 (HSP90). HSPs are a group of molecular chaperons that play an 
important role in ensuring proper protein folding, establishing correct conformation, and 
preventing unwanted aggregation [45]. HSP90 is a member of the HSP family that is 
expressed in the cytoplasm of most human cells and is involved with the conformational 
maturation and stabilization of various clients involved in cell cycling, receptor maturation 
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and function, signal transduction, protein trafficking, innate and adaptive immunity, and 
apoptosis [46, 47]. Cancerous HSP90 is highly active, interacting with many more co-
chaperons than normal, and using much more ATP than normal. As a result of this, HSP90 
starts misfolding its client proteins, several of which are oncoproteins. HSP90 is therefore 
studied as a potential therapeutic target of cancer treatment by inhibition, with various 
HSP90 inhibitors being researched and developed. For example, targeted therapy with the 
selective HSP90-inhibitor 17-AAG shows potential as an antileukemic strategy against AML, 
and together with various other HSP90 inhibitors, have entered phase I/II clinical trials [8, 
46-48]. HSP expression has also been linked to AML relapse and increased chemoresistance 
[48]. 
 
Another interesting strategy for targeted treatment is the induction of RNA interference 
(RNAi), wherein one introduces double-stranded small interfering RNA (siRNA) sequences 
into the cell cytoplasm to post-transcriptionally downregulate gene expression by sequence 
specifically targeting messenger RNA (mRNA) strands [49]. The gene silencing is achieved by 
siRNA binding to the RNA-induced-silencing-complex (RISC), which is then guided to the 
sequence complementary mRNA strand. This results in the mRNA being cleaved by RISC, and 
finally degraded, thus ceasing the strands protein translation. By exploiting the naturally 
occurring RNAi machinery of the cell, introducing siRNA can be done to target and silence a 
specific gene in the malignant cell. Ideally, this would disrupt the synthesis of an important 
protein, and thus either prevent malignant function of the cell or cause enough cellular 
stress so induce apoptosis. With this strategy, the siRNA molecule would be the therapeutic 
agent, and is as such studied as a low-toxicity alternative strategy to more common 
chemotherapeutic treatments. But as with other therapeutics, siRNA faces challenges when 
delivered systemically in vivo. In particular, it needs assistance with crossing the plasma 
membrane to enter the cytoplasm, due to being charged and hydrophilic. The siRNA is also 
susceptible to nuclease-mediated degradation in biological fluids, as well as kidney filtration, 
phagocyte uptake, and aggregation with serum proteins in the blood [8, 50]. So while siRNA 
can be stabilized through chemical modifications, it still requires a delivery system, not only 
to reach the target cells, but for internalization into the cell. 
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2.6 - Aims 
The aim of this work is to study the production and characterization of liposomal and PLGA-
based nanocarriers, and to evaluate their suitability as drug delivery platforms for anti-AML 
drugs. I specifically wanted to answer the following questions: 
Does the nanocarrier production result in desirable size and size distributions? Different 
types of nanocarriers are produced by different methods, and it is relevant to know if the 
methods result in favorable features, such as small size and narrow size distributions. Size is 
a crucial aspect of nanotechnology, and in this case, for the behavior and properties of the 
nanocarriers. 
Can the nanocarriers be loaded with relevant drugs or pharmaceuticals? For nanocarriers to 
serve their purpose as vehicles for drug transport, they first need to effectively and reliable 
encapsulate or bind with the relevant drug. This needs to be assessed, as the drug-
nanocarrier interaction differs greatly depending on type and properties of the nanocarrier, 
the drug or pharmaceutical, and the loading method. Given successful nanocarrier drug 
loading, how well are the drugs and pharmaceuticals retained in the nanocarriers? Are they 
retained or released, and if the latter, to what degree? While any leakage is unwanted, as it 
would decrease the therapeutic efficacy of the formulation and increase potential side 
effects, it may not necessarily be a problem if within acceptable doses. It is however 
something that should be considered and examined. 
Are the nanocarriers well-internalized into the AML cells? Another important factor to 
consider, is their nanocarrier-cell interaction, and whether the nanocarriers can reach the 
cells and internalize into the cell cytoplasm. This step is crucial as the drugs not only need to 
enter the cell to be effective, but in some cases require a nanocarrier for internalization. 
Furthermore, if somehow internalized, will the drug- or pharmaceutical loaded nanocarriers 
exhibit sufficient efficacy towards AML cells? Do they contribute to increased potency, or 
simply similar results, or no effect at all? A stronger effect using nanocarriers may not be 
necessary for them to be considered useful, as a similar effect does not take into account 
other benefits of using nanocarriers. 
The project will examine the loading and delivery of drugs and molecules such as CPZ, 




3. Materials and methods 
3.1 - Chemicals and reagents 
Chlorpromazine hydrochloride (CPZ), dynasore hydrate (DH, genistein (GS), formaldehyde, 
chloroform, acetonitrile (ACN), trifluoracetic acid (TFA), Phosphate buffered saline tablet 
(PBS), poly(vinyl alchohol) (PVA, Ave. MW = 10 000 g/mol), Nile Red (NR), cholesterol 
(CHOL), uranyl acetate, was purchased from Sigma-Aldrich (St. Louis, MO, US). EmulmetikTM 
930 phosphatidylcholine (PC) was purchased from Lucas Meyer Cosmetics (Champlan, 
France). ATTO488 fluorescent label conjugated to 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine (ATTO488-PE) was purchased from ATTO-TEC GmbH (Siegen, 
Germany). 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-2000] (ammonium salt) (PEG-PE), 1,2-Dioleoyl-3-Trimethylammonium-Propane 
(chloride salt) (DOTAP) was purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). 
Lipoid E PC-3 Hydrogenated egg phosphatidylcholine (HEPC) from Lipoid GmbH 
(Ludwigshafen, Germany). Resomer® RG 505 Poly(D,L-lactic-co-glycolide) (PLGA, 50:50 
lactic:glycolide, MW 54 000–69 000 g/mol) was purchased from Evonik Röhm Pharma GmbH 
(Essen, Germany). Poly(ethylene glycol)-poly(DL-lactide-co-glycolide) (PLGA-PEG) 50:50 
Resomer PEG type RGP d 50105 (MW = 50 000 g/mol) (diblock, 10% PEG with 5000 Dalton) 
was purchased from Boehringer Ingelheim (Ingelheim, Germany). Lipofectamine® 2000 
transfection reagent, Ambion® Silencer® GFP (eGFP) siRNA, ProLong® Gold Antifade 
Mountant with DAPI, and Hoechst 33342 fluorescent DNA staining reagent was purchased 
from Thermo Fisher Scientific (Waltham, MA, USA). VECTASHIELD® Antifade Mounting 
Medium with DAPI was purchased from Vector Laboratories (Burlingame, CA, US). X-treme 
Gene 9 DNA Transfection Reagent, WST-1 cell proliferation reagent from Roche Diagnostics 
GmbH (Mannheim, Germany). NAT-inhibitor peptide was provided by Dr. Thomas Arnesen, 
Department of Molecular Biology, University of Bergen. 
 
3.2 - Nanocarrier production  
3.2.1 - Liposomal formulations 
Three different liposomal formulations were produced, all with a final lipid concentration of 
5 mM. Fluorescent liposomes were prepared using PC, CHOL, PEG-PE, at a lipid molar ratio of 
1.8:1:0.1, and adding ATTO488-PE at 0.5% of total PC content. The lipid composition of 
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liposome-siRNA complex (lipoplex) consisted of HEPC, CHOL and DOTAP, with a 1:1:1 lipid 
molar ratio. NAT-inhibitor peptide loaded liposomes were made with HEPC and CHOL in a 
2:1 lipid molar ratio. 
 
The lipids were dissolved in chloroform to 2.5 mg/ml and added to a round bottom flask. 
Using a rotary evaporator, a lipid film was created by evaporating off the chloroform under 
mild vacuum in room temperature at 200 mbar, changing to full pump capacity (around 7 
mbar) when the film was dry to remove residual chloroform. The samples were kept dark to 
avoid fading of the fluorescent probe. The lipid film was rehydrated by adding PBS (5mmol 
lipid/l aqueous phase) and vortexing the round bottom flask until no film was visible on the 
glass. For HEPC liposomes, the hydration solution was heated beforehand to 70 ºC. The 
hydrations solution for siRNA- and peptide-loaded liposomes were RNAse free PBS or a 2 
mg/ml peptide solution in PBS respectively. To obtain small unilamellar vesicles (SUV, 
liposomes), the resulting suspension of large multilamellar vesicles (LMV) were extruded 
through 0.2 µm and 0.1 µm Whatman® Nucleopore Track-Etched membrane filters, 11 times 
per filter, using a Mini Extruder from Avanti Polar Lipids, Inc. (Alabaster, AL, US). HEPC 
liposomes were extruded at 70 ºC using a heating block. 
 
To produce lipoplex with a 3:1 ratio of DOTAP:nucleotide, 50 µM Ambion® Silencer® GFP 
(eGFP) siRNA solution in RNase-free water was added to liposomes and left to interact for 1-
2 hours in a 60 °C water bath with occasional vortexing. HEPC:CHOL liposomes with and 
without the HSP90-inhibitor 6BrCaQ [51] were a kind gift from Gillian Barratt and Felix 
Sauvage, Institut Galien, Faculté de Pharmacie, Université Paris 11-Sud. The concentration of 
6BrCaQ in the liposome suspension was 247 µM. To produce liposomes containing the NAT-
inhibitor, a 2 mg/ml solution of the peptide in PBS was used to hydrate the HEPC:CHOL lipid 
film. 
 
3.2.2 - Solid PLGA polymer nanoparticles 
PLGA and PLGA-PEG nanoparticles were prepared using the emulsion-evaporation technique 
with PVA as the stabilizing surfactant. An organic solution was first made using 50 mg 
polymer and 2 ml chloroform. For drug-loaded nanoparticles, 10 mg of chlorpromazine (was 
added to the organic solution, while 1 mg of Nile Red was added for fluorochrome-loaded 
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nanoparticles. A 10 ml solution PBS (pH 9.5) with 0.5% (w/v) PVA was quickly added to the 
organic solution. In quick succession, the emulsion was briefly shaken, before being exposed 
to 1 minute of vigorous vortexing, followed by 1 minute of sonication using a Misonix 
XL2020 sonicator (Farmingdale, NY, US) at 30 watts output. The removal of chloroform was 
done by using mild vacuum in a rotavapor, going from 250 to 100 mbar, for at least 1 hour at 
room temperature. To remove excess surfactant, the nanoparticles were washed twice by 
centrifugation (5500 x g for 15 minutes) and resusupended in 10 ml pH 9.5 PBS. The 
nanoparticle solutions were stored at 4 °C in the dark. CPZ-loaded nanoparticles were used 
at the day of production. 
 
3.3 - Nanocarrier characterization: Size, polydispersity and morphology 
Size and polydispersity index (PdI) characterization of all nanocarriers produced, as well as 
zeta potential characterization of cationic DOTAP liposomes, was done by dynamic light 
scattering (DLS) using a Zetasizer (Malvern Instruments Ltd., Malvern, UK) with Zetasizer 
Software (version 7.10) and automated settings, and three measurement runs for each 
sample. The nanocarrier solutions were diluted 1:50 in PBS (pH 7.4) suspension buffer for 
size measurement, and in 5% sucrose in MilliQ water solution for zeta potential. For samples 
containing more than one size population, the “Multiple narrow modes / high resolution” 
analysis model was chosen in the software.  
 
For imaging using transmission electron microscopy, nanocarrier samples were prepared by 
negative staining technique. This was done by applying the grid with the formvar-coated side 
faced down onto a drop of nanocarrier solution for 60 seconds, followed by washing the 
same surface five times using five different drops of water for 5 seconds each, before finally 
holding grid on top of drop of 2% uranyl acetate solution for 10 seconds, and next dried. 
Images were obtained using a transmission electron microscopy. A JEOL 1011 transmission 
microscope with a MORADA camera and OIS computer system was used for the liposomes, 
while a JEOL JEM-1230 with a GATAN multiscan camera was used for the nanoparticles. 
Image scale determination and size analysis of the liposomes and nanoparticles was done 
using ImageJ software tool [52]. 
 
16 
3.4 - Drug-nanocarrier interaction 
3.4.1 - High performance liquid chromatography (HPLC) 
Nanoparticle solutions were, immediately after synthesis and washing, set to stir at 37 °C on 
a Thermomixer Comfort (Eppendorf AG, Hamburg, Germany), with samples being taken at 
various time points. Separation of nanoparticles from supernatant was done by 
centrifugation at 3500 x g for 15 min. This was followed by dissolving the pellet in a 3:2 
volume-ratio of acetonitrile (ACN) and MQ, and diluting the supernatant in a 3:2 volume-
ratio solution of ACN and 0.05% trifluoracetic acid (TFA) in MQ.  
 
High performance liquid chromatography (HPLC) was used to study the drug-loaded 
nanoparticle for encapsulation efficiency over time, as well as in vitro drug release rate. The 
samples were injected into a reversed phase HPLC column (Kromasil 100-5 C18 150-4.6 mm, 
Akzo Nobel, Sweden) connected to a Merck-Hitachi LaChrom HPLC system (VWR, 
WestChester, USA) with a L-7100 pump, L-7200 autosampler, D-7000 interface, L-7455 diode 
array detector, and a L-7614 degasser. A chromatogram was recorded at wavelength 255 nm 
and used for quantification of drug content. 
 
The setup was run for 13 minutes per sample, with a 1 ml/min flow rate, ACN and 0.05 % 
TFA in MQ as the mobile phases A and B, respectively. The mobile phase gradient was as 
follows: 60 % A and 40 % B for the first 30 seconds, then increase A to 100 % for the next 5.5 
min, followed by a 1 min wash of the column with 100 % A. Finally, the starting conditions 
were reestablished during a two min gradient, and the column equilibrated with 60 % A and 
40 % B for four min before the next injection. CPZ eluted as a single peak at 3.0 min, and the 
area calculated from the chromatogram obtained at 255 nm wavelength was used to 
quantify CPZ content in the samples. A standard curve for CPZ was made by measuring CPZ 
solutions in in a 3:2 volume-ratio ACN:MQ with concentrations of 3, 10, 30, 100 and 300 µM. 
 
3.4.2 - UV-Vis Spectrophotometry 
Analysis of drug concentration in nanocarriers was also done using the Varian Cary 50 Bio 
UV-Visible Spectrophotometer with the Cary Win UV Scan Application (Ver. 3.00) (Agilent 
Technologies, Santa Clara, CA, US). This provided the actual drug concentration of the 
various nanoparticle batches used for cellular experiments. For CPZ-loaded nanoparticles, 
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the samples were prepared in the same manner as for HPLC, while NAT-peptide loaded 
liposomes were resuspended in MQ after gel-filtering and PBS evaporation. 
 
3.5 - Cell lines 
MOLM13 [53, 54] and MV4-11 [54, 55] AML cell lines were cultured in RPMI-1640 and 
Iscove’s Modified Dulbecco’s Medium (IMDM) respectively, while both NRK (ATCC #: CRL-
6509) and HEK293 (ATCC #: CRL-11268) cell lines were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM). All culture media were from Sigma-Aldrich (St. Louis, MO, US), and were 
supplemented with 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA), 100 IU/ml 
penicillin and 100 mg/ml streptomyocin (Cambrex, Belgium). Iscove’s medium was 
additionally enriched with 8 mM L-glutamine. All cell lines were maintained in a humidified 
atmosphere containing 5 % CO2 at 37 °C. MOLM13 cells stably expressing green fluorescent 
protein (GFP) were provided by Prof. Stein Ove Døskeland, Department of Biomedicine, 
University of Bergen. AML blasts from patients were provided by Benedicte S. Tislevoll and 
Bjørn T. Gjertsen, Department of Clinical Science, University of Bergen. The blasts were 
suspended in IMDM supplemented with 20% FBS, and used for experimentation on the day 
of sampling. 
 
3.6 - Fluorescent nanocarrier cell uptake studies 
3.6.1 - Examination of cellular internalization of nanocarrier by flow cytometry 
Cells (with a 3.5 105/ml cell suspension concentration) were incubated with fluorescent 
nanocarriers at desired concentrations or times, and the experiments stopped by washing 
the cells twice with room temperature PBS and resuspending them in PBS. The cells were 
kept dark and on ice and immediately analyzed by flow cytometry using a FACS Accuri C6 (BD 
Biosciences, San Jose, CA, US), with the following settings: 488 nm laser, 533/33 nm filter for 
ATTO488 and 585/40 nm filter for Nile Red, fast fluidics (66 µl/min), 20 000 non-gated 
events. Analysis of the measured events was done using the Accuri C6 software (BD 
Biosciences), with gating to exclude dead cells, debris and doublets. Mean fluorescence 
intensity of cells was used as the measurement of nanocarrier internalization. 
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3.6.2 - Visualization of nanocarrier uptake by confocal microscopy  
For confocal microscopy, cells added various nanocarriers were fixed with 2% formaldehyde 
fix for at least 30 min at RT in the dark. The cells were then centrifuged at 200 x g for 5 min, 
resuspended in PBS, cytospun with a Shandon Cytospin 3 centrifuge onto glass slides at 300 
x g for 10 min and mounted with ProLong Gold mounting medium with DAPI, and sealed 
with glass cover slips. Samples were stored dark and at 4 °C until imaging. Images of the 
mounted samples were obtained using a Leica TCS SP5 confocal microscope (Leica 
Microsystems GmbH, Wetzlar, Germany) together with the Leica Application Suite software 
version 2.7.3 and an HCX PL APO CS 63.0x1.40 OIL UV objective. The 488 nm Argon laser was 
used for excitation of both ATTO488 and Nile Red fluorochrome, with the 405 nm UV laser 
being used for imaging DAPI-stained nuclei. 
 
3.6.3 - Nanocarrier uptake inhibition studies 
To study the cellular uptake path of liposome, uptake inhibition experiments were done 
using MOLM13 cells, seeded in 48-well plates with a cell concentration of 350 000 cells/ml. 
The cells were incubated with various inhibitors for 2 hours before the adding and 
incubating the cells with fluorescent liposomes for 15 min. The inhibitors examined were: 
chlorpromazine, dynasore hydrate, and genistein. Both the effects of liposome amount and 
inhibitor concentration on liposome uptake were studied. At the end of the experiment, the 
cells were studied by flow cytometry and/or confocal microscopy. For the flow analysis, the 
cells were washed twice with and resuspended in PBS, and analyzed using the Accuri C6 and 
counting up to 20 000 events with fast fluidics (66 µl/min). Confocal microscopy with the 
Leica SP5 was done after fixing cells for 1 hour with 2 % formaldehyde fix in PBS, 
cytospinning them onto slides at 300 x g for 5 min, and mounting them with ProLong Gold 
with DAPI. 
 
3.7 - Nanocarrier cytotoxicity studies 
Cytotoxicity studies of nanocarrier formulations on cell lines (between 3.5 and 4.5 x 105 
cells/ml for cell suspensions and 0.7 x 105 cells/ml for adherent cells) were done using 
metabolic activity assay and/or fluorescence microscopy of nuclei stained cells. The cells 
were seeded in 96-well plates and kept in humidified atmosphere (37 °C, 5% CO2). Cells were 
incubated for up to 72 hours with either PBS, free drug, or drug-loaded or empty 
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nanocarriers. AML cell lines were seeded in plates at the day of the experiment, while the 
adherent NRK cells were seeded at least a day before the experiment to allow attachment to 
the substratum. 
 
WST-1 reagent was preheated to 37 °C and added to each well 24 hours after start of 
experiment. After 2 hours of incubation, the wells were measured for absorbance using a 
TECAN Infinite M200 Pro plate reader and Magellan software (version 7.2), with 450 and 620 
nm as absorbance and reference wavelength, respectively. 
 
Cells incubated with WST-1 and analyzed with plate reader were fixated directly in the wells 
by adding 4% formaldehyde fix in PBS containing 0.01 mg/ml Hoechst33342 DNA dye, to 
yield a final concentration of 2% formaldehyde. For cells incubated over several days, 
samples were taken and fixed with 2% formaldehyde fix in PBS. The cells were left in the 
dark at least overnight at 4 °C to allow for nuclear staining before imaging with Axiovert 
200M fluorescence microscope (Carl Zeiss, Oberkochen, Germany), at either 20X or 40X 
magnification. From the images, the percent of apoptotic cells were determined by counting 
at least 100 cells from each image. Normal cells typically have evenly stained bean-shaped 
nuclei with some variations in intensity staining, whereas apoptotic nuclei are condensed, 
stain much brighter, and are sometimes fragmented. Sometimes the nuclei of dead cells 
swell instead. See Supplementary Figure 1 for examples of normal and apoptotic nuclei. 
 
3.8 - siRNA delivery and gene knockdown studies 
3.8.1 - GFP plasmid and siRNA transfection 
HEK293 cells were seeded in a 24-well plate at 370 000 cells/ml and left overnight in 
incubator to adhere. GFP transfection of the cells was then done by drop-wise adding a GFP-
expressing plasmid and transfection reagent solution to the cells. This solution was made by 
mixing 5 µl of X-treme Gene 9 DNA Transfection Reagent with 2.5 µg GFP plasmid in 200 µl 
non-enriched DMEM medium, and leaving it at RT for 30 min before use. After 24 hours of 
incubation, the cells were transfected with a solution containing the GFP gene silencing 
siRNA using Lipofectamine as transfection reagent. This solution was made by mixing 20 
pmol siRNA and 1 µl Lipofectamine in each their 50 µl volume of unenriched medium for 5 
min, before mixing the two and incubating at RT for 20 min before use. The siRNA 
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transfection solution was added drop-wise and the cells were incubated overnight. 
Fluorescence microscopy of the living cells was performed to verify expression of GFP, 
followed by washing, trypsinating, centrifugation at 1500 x g for 5 min and resuspending the 
cells in 2 % formaldehyde fix in PBS with Hoechst 33342. Flow cytometry analysis was then 
done with the 488 nm excitation laser and FL1 533/30 nm filter, medium fluidics (35 µl/min), 
collecting 20 000 events. Gating of recorded events was done for living cells, singlets and 
GFP fluorescence. 
 
3.8.2 - Liposome-siRNA delivery to AML cells 
GFP knockdown experiments were done with GFP-expressing MOLM13 cell lines, seeded 
with a 600 000 cells/ml concentration in a 48-well plate. As a control, MOLM13 wt cells were 
included in the experiment. The cells were incubated with either free GFP gene silencing 
siRNA, empty or siRNA-loaded liposomes produced as described in “Nanocarrier 
production”. Samples were taken after 24, 48 and 72 hours, and immediately analyzed with 
Accuri C6 flow cytometer while kept dark and on ice. The flow cytometry was done using 488 
nm excitation laser and FL1 533/30 nm band-pass filter, counting 40 000 events with fast 
fluidics (66 µl/min) and gating for cells and GFP fluorescence. Analysis was done by 
determining the percentage of fluorescent cells and mean fluorescence intensity of the 





4.1 - Characterization of liposomes and solid polymeric nanoparticles 
In order to properly assess the size, polydispersity, and morphology of the different 
nanocarriers produced, we analyzed them by dynamic light scattering (DLS) and transmission 





































































Figure 1 – DLS size distribution characterization of liposomal and polymeric nanocarriers. Using a Zetasizer, 
DLS measurements for size (d.nm) against intensity were done on the following produced nanocarrier 
formulations: PEGylated liposomes (A), cationic liposomes (B), CPZ-loaded PLGA (C) and PLGA-PEG (D) polymer 
nanoparticles. Each graph shows 3 size distribution measurements of a single, representative nanocarrier batch, 
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Figure 2 – Characterization of liposomal nanocarriers by transmission electron microscope. Transmission 
electron microscopy images of (A) PEGylated liposomes and (B) cationic liposomes negatively stained with 2 % 
uranyl acetate for 10 seconds, obtained with a JEOL JEM-1011 electron microscope. Size distribution analysis of 
liposome diameter (d.nm) measured by the ImageJ software (https://imagej.nih.gov/ij/) based on TEM images 
was done using SigmaPlot software (Systat Software Inc. San Jose, CA) and are shown in histograms for 
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Figure 3 – Characterization of drug-loaded polymer nanoparticles by transmission electron microscope. 
Transmission electron microscopy images of chlorpromazine (CPZ) loaded nanoparticles made of PLGA (A) or 
PLGA-PEG (B) negatively stained with 2 % uranyl acetate for 10 seconds, obtained with a JEOL JEM-1230 
electron microscope. Size distribution analysis of nanoparticle diameter (d.nm) measured by the ImageJ 
software (https://imagej.nih.gov/ij/) based on TEM images was done using SigmaPlot software (Systat 




4.1.1 - Liposomes 
Liposomes, which were extruded through a 100 nm membrane filter of a certain size, and 
could be analyzed with the DLS using single peak mode settings in the Malvern software 
package. Both the PEGylated and the cationic liposomes showed a Z-average above the 
pore-size of the membrane (Table 1), and the PdI of both liposomes was below 0.130, with 
the cationic showing the higher Z-average and PdI. Moreover, the peak-size estimated from 
the DLS readings by the Zetasizer software differed from the Z-average, showing single, 
narrow peaks with slightly higher diameters (Figure 1A-B). When the liposomes were studied 
by TEM, we found that the liposomes appeared as deflated spheres (Figure 2A-B). However, 
the PEGylated liposomes were characterized by being more structurally distinct and intact 
(Figure 2A), while the cationic liposomes appeared less rigid (Figure 2B), but still apparently 
intact. Morphometry of the diameter of the liposomes was performed, and the histograms 
(Figure 2C-D) show results similar to the DLS data, with mean diameter and standard 
deviation of 112.7 ± 36.5 nm and 180.6 ± 58.5 nm for the PEGylated and cationic liposomes 
respectively (Table 1).  
 
Liposome solutions were also analyzed with DLS for Zeta-potential (mV) using a DTS1061 
folded capillary cell (Malvern Instruments Ltd., Malvern, UK). Zeta-potentials of neutral, 
PEGylated liposomes were measured at -22.2 mV and -3.82 mV at 3% and 1% nanocarrier 
V/V concentration in 5% sucrose MQ solution, respectively. For cationic liposomes, Zeta-
potentials of 47.5 mV and 48.6 mV were registered for the 3 % concentration, and 35.8 mV 
for 1 % concentration. 
 
4.1.2 - Solid PLGA nanoparticles 
As the PLGA and PLGA-PEG nanoparticles had not been size selected by filtering, they were 
likely to consist of several sub-populations of different size, and therefore analyzed with 
multiple peak mode on the DLS (Figure 1B-C). For PLGA and PLGA-PEG the Z-average and PdI 
ranged consistently around 370 nm and 0.200, respectively (Table 1). Peaks around the 200–
600 nm range were however regular in nanoparticle batches, as shown for both PLGA and 
PLGA-PEG in Figure 1C and D. As with the liposomes, the PLGA and PLGA-PEG nanoparticles 
were prepared and imaged using TEM (Figure 3A-B), and analyzed for size distribution 
(Figure 3C-D). Due to variances in negative staining process however, PLGA-PEG 
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nanoparticles show up more structurally defined compared to the PLGA which features 
staining solution accumulated around the nanoparticles. Mean size and SD were shown to 
be 147.9 ± 73.0 nm and 150.1 ± 90.3 nm for PLGA and PLGA-PEG respectively (Table 1). 
 

























128.8 0.080 142.1 44.73 112.7 36.5 49.8 258.8 
Cationic 
liposomes 
191.4 0.128 218.9 80.41 180.6 58.5 88.6 365.6 





147.9 73.0 56.3 459.3 
PLGA-PEG 365.2 0.158 402.7 135.9 150.1 90.3 50.8 568.5 
 
4.2 - Drug loading, encapsulation efficiency and release rate of polymer nanoparticles 
 
Table 2 – Spectrophotometric measurements of CPZ content of CPZ-loaded PLGA NP 






Pellet 592.6 ± 110.6 
19.8 % 3.3 % 
Supernatant 87.7 ± 47.2 
PLGA-PEG 
Pellet 958.3 ± 116.5 
31.9 % 5.3 % 
Supernatant 45.7 ± 40.8 
1: Data are mean of 5 different batches, with standard deviation, with pellet concentration calculated based 
on original outtake solution volume. 
2: Based on pellet concentration, and of total CPZ amount added. 
3: Based on pellet concentration, and of total nanoparticle dry weight. 
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We used solid PLGA nanoparticles to encapsulate CPZ, based on the article published by 
Halayqa et al. [56]. CPZ content was measured using UV-Vis spectrophotometry and by 
HPLC, and while HPLC is a more accurate method as it separates compounds and provides 
for less background signal, the methods gave similar results. Average encapsulation 
efficiency and drug loading for five different batches of PLGA and PLGA-PEG nanoparticles 
was determined by spectrophotometric readings, and are given in Table 2. It is noteworthy 
that the PLGA-PEG nanoparticles have higher drug loading than the PLGA nanoparticles. 
Next, the release rate over time of CPZ from PLGA and PLGA-PEG nanoparticles was 
examined by HPLC. Immediately after finishing producing and washing the nanoparticles, the 
nanoparticle solution was dissolved in PBS, pH 9.4, and set to shake at 37 °C in glass vials. 
500 µl samples were taken at given time points, up to and including 72 hours, and spun 
down to separate nanoparticles from the supernatant. From the resulting chromatograms 
from the area of the CPZ elution peaks and CPZ standard curve, the CPZ concentration 
retained in nanoparticles and released into supernatant was calculated, and plotted as a 
function of time (Figure 4). For PLGA, neither pellet nor supernatant show any significant 
change in CPZ concentration, with values around 600 µM and 200 µM, respectively, for the 
whole period of time. For the PLGA-PEG, the pellet starts with a higher CPZ concentration 
than PLGA, but sharply decreases during the 12 first hours from 1000 µM, while the 
supernatant increases from 60 µM, with both samples meeting at around 350 µM after 72 
hours of mixing. Combining the pellet and supernatant CPZ concentration, gives a total CPZ 
concentration at 0 hours and 72 hours of 750 and 800 µM for PLGA, and 1060 and 700 for 
PLGA-PEG. 
 
To achieve highest possible nanocarrier mediated drug delivery to AML cells, the 
nanocarriers should be internalized. To investigate this, AML patient blasts isolated from 
bone marrow were exposed to fluorescently labeled liposomes, with quantitative analysis of 
dose-dependent uptake of liposomes done using flow cytometry, looking at both the mean 
fluorescence intensity (MFI) of cells as well as the percentage of cells with fluorescence. 
More thorough studies were done by exposing MOLM13 and MV4-11 AML cells to liposomes 
and PLGA nanoparticles, and measuring the nanocarrier internalization by flow cytometry 
and confocal microscopy. Flow cytometry was employed to examine dose-dependent and 





Figure 4 – Drug encapsulation and release of CPZ-loaded PLGA and PLGA-PEG nanoparticles. CPZ-loaded 
nanoparticles were left to stir in PBS (pH 9.4) at 37 °C in glass vials at 750 RPM. At the given time-points, 
samples were taken and analyzed for CPZ-content by HPLC analysis as described in the Methods section. The 
data shows chlorpromazine concentration of nanoparticle pellet (P), resuspended in original sample outtake 
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4.3 - Uptake of liposomal and PLGA nanoparticles in acute myeloid leukemia cells 
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Figure 5 – Change in fluorescence of patient bone marrow cells treated with fluorescent liposomes. Bone 
marrow cells (350 000 cells/ml) from patient were treated with PEGylated liposomes labelled with ATTO488, 
with either different V/V nanocarrier concentrations (0 - 20 %/0 - 100 µl) for 10 min. Flow cytometry analysis 
was performed after washing the cells twice with PBS. Analysis of data was done using the Accuri C6 software, 
with gating for living cells in (A). First gating strategy, done for measuring mean fluorescence intensity of all 
cells, is shown in B and E, while the second gating strategy, based on percentage of cells that are fluorescent 
adjusted for control autofluorescence, is shown in E and F. B and C are from a control sample while E and F are 
from a max concentration sample. Mean fluorescence values are shown for all samples of a parallel in 
fluorescence histogram (D). Mean fluorescence data is plotted and adjusted for control in G, with percentage 
data plotted in H, both against the sample’s respective liposome V/V concentration. SigmaPlot was used to 
calculate the mean of samples from parallels, with standard deviation and linear regression. Results are from a 
single experiment done with 3 parallels. 
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Since the target for the nanocarriers will not be cell lines, but patient cells, the 
internalization of liposomes into AML patient blasts were investigated. AML blasts from 
patient bone marrow were treated for 10 min with PEGylated and ATTO488-labeled 
liposomes, and analyzed using flow cytometry. Analysis of the flow data was done in two 
ways based on gating strategy (Figure 5A-F): looking at MFI of cells (Figure 5B and E), and 
percentage of cells with ATTO488 fluorescence based on untreated control (Figure 5C and F). 
A linear increase was seen for both MFI of cells (Figure 5D and G) and percentage of 
fluorescent cells (Figure 5H). 
 
For both dose-dependent and time-dependent experiments with liposomes on MOLM13 
cells (Figure 6A-B), and MV4-11 cells (Figure 6F-G), the MFI increased in a linear manner, 
with no apparent saturation point. Moreover, we noted that the two cell lines had equal 
ability to internalize the liposomes with respect to dose (Figure 6A and F), but that MOLM13 
cells appeared to have a faster internalization than the MV4-11 cells (Figure 6B and G). In 
order to assess whether the increase in fluorescence seen in the flow cytometry results were 
due to internalization or merely association of fluorescent liposomes on the cellular 
membrane, the cells were studied by flow cytometry. Here we could replicate the dose-
dependent increase in fluorescent intensity (Figure 6C-E and H-J). Moreover, the 
fluorescence is located in the cytoplasm of the cells, rather than on the cellular surface. 
However, it is notable that the MOLM13 cells treated with the highest concentration of 
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Flow cytometric results from MOLM13 treated with NR-loaded PGLA and PLGA-PEG are 
shown in in Figure 7A and B, and Figure 7C and D respectively, with A and C plotting effect of 
nanocarrier dosage on MFI of cells, and B and D plotting effect of incubation time on MFI. 
With both PLGA and PLGA-PEG, the time-experiments seem to show a threshold for 
internalization, with both reaching a similar MFI (Figure 7B and G, respectively). While there 
is a linear dose-response curve in the PLGA nanoparticles (Figure 7A), the curve flattens 
slightly in the highest concentrations in cells treated with PLGA-PEG nanoparticles (Figure 
7F). Note PLGA-PEG also shows higher MFI values than PLGA for dose-experiment, and at the 
start of the time-experiments. As with the liposomes, the confocal images revealed 
intracellular localization of the fluorescence. With the PLGA and PLGA-PEG nanoparticles, 
the fluorescence appears as spots inside the cells. 
 
  
Figure 6 – Uptake of fluorescent liposomes in AML cell lines. MOLM13 (A-E) or MV4-11 cells (F-J) were treated 
with various V/V concentrations (A and F) for 10 min, or 2% V/V concentration for different time-points (B and G) of 
PEGylated liposomes labeled with ATTO488, before wash and analysis of fluorescence intensity by flow cytometry. 
Samples were also fixed in 2% buffered formaldehyde (pH 7.4) and liposome internalization was visualized by 
confocal microscopy (C-E and H-J). The results in A, B, F and G are average from two independent experiments 
performed in triplicates and standard deviation, featuring linear regression made using Sigmaplot. The scale bar in 
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4.4 - Nanocarrier uptake inhibition studies 
 
 
Uptake of nanoparticles in cells can be by different pathways. In order to get an overview of 
the mechanisms involved in the internalization of liposomes, cells were treated with either 
of the following inhibitors before addition of fluorescent liposomes: Chlorpromazine (CPZ), 
and dynasore hydrate (DH), both inhibitors of chlatrin mediated endocytosis; genistein (GS), 






















































Figure 8 – Uptake of liposomes in MOLM13 cells after treatment with endocytic inhibitors. MOLM13 cells 
were treated with 5% V/V concentration of ATTO488 fluorescent liposomes with inhibitors and at various 
concentrations (A), or with 1X inhibitor concentration and various V/V concentrations of liposome (B). Inhibitors 
were chlorpromazine (CPZ), dynasore hydrate (DH), and genistein (GS). 1X concentrations of inhibitors: CPZ (10 
μg/ml), DH (27 μg/ml), GS (54 μg/ml). Incubation with inhibitors was done for 2 hours before adding liposomes 
and incubating for 15 min. Cells were then washed twice with PBS and analyzed for liposome internalization 
with an Accuri C6 flow cytometer as described in the methods section. The data are from one experiment. 
A B 
Figure 7 – Uptake of fluorochrome-loaded nanoparticles in MOLM 13. PLGA (A-E) or PLGA-PEG (F-J) 
nanoparticles were used to treat MOLM13 cells, either with various nanoparticle V/V concentrations (A and F) 
for 10 min, or 2% V/V concentration for different time-points (B and G), before wash and analysis of 
fluorescence intensity by flow cytometry. Samples were also fixed in 2% buffered formaldehyde (pH 7.4) and 
nanoparticle internalization was visualized by confocal microscopy (C-E and H-J). The results in A, B, F and G are 
average from single experiment performed in triplicates and standard deviation, featuring linear regression for 
A, and fitted regression curve for B-D made using Sigmaplot. The scale bar in the confocal micrographs 
represent 10 μm. See the Methods section for details on flow cytometry and confocal. 
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For the experiment using different inhibitor concentrations, the mean fluorescence of the 
cells is plotted relative to the control sample, which is cells incubated with liposomes but 
without any inhibitor (Figure 8A). For cells incubated with CPZ, the mean fluorescence 
started at 100 % fluorescence of control with 0.1X inhibitor concentration, and then 
decreased slightly, but returned to 100% mean fluorescence for 3X concentration. The 
opposite behavior was noted for the GS, where the 0.1X concentration sample started at 100 
% of control, but instead increases slightly for 1X concentration, before dropping to 100 %. 
For cells treated with DH, the mean fluorescence starts at 110 %, and continued to increase 
in a dose-dependent manner.  
 
For the experiment using different liposome concentrations, MOLM13 cells were treated 
with the various inhibitors using 1X inhibitor concentration, or with either DMSO or RPMI 
medium as controls (Figure 8B). Gating was done in same manner, but with mean 
fluorescence values adjusted for the 0 % concentration control samples containing inhibitor 
but not liposomes. For all treatments, including DMSO and RPMI controls, the mean 
fluorescence increased with increasing dosage of fluorescent liposomes, and no treatment 
stood out as having strikingly lower or higher fluorescence. RPMI samples reached the 
highest mean fluorescence at 3400, while DMSO the lowest at 2200. Both CPZ and GS ended 
at 3000 mean fluorescence for highest liposome concentration, while DH at 2600. 
 
4.5 - Anti-AML cell activity of CPZ-loaded PLGA nanoparticles 
To examine the potential cytotoxic effect of nanoparticle-encapsulated chlorpromazine 
(CPZ), MOLM13 and NRK cells were treated with different concentrations of free CPZ, CPZ 



































































































Figure 9 – Cytotoxicity induced by CPZ-loaded nanoparticles towards MOLM13 and NRK cells. Cells were 
incubated for 24 hours at 37 °C with various concentrations of empty and CPZ-loaded PLGA and PLGA-PEG 
nanoparticles as well as free CPZ. A and B shows the metabolic activity of the cells relative to control, measured 
by conversion of the WST-1 reagent, described in detail in the Methods section. After reading the plate, the cells 
were fixed in 2% buffered formaldehyde added the DNA stain Hoechst 33342, and the percent apoptotic nuclei 
determined by microscopy and adjusted for control (C and D). The data in A and C are from 3 independent 
experiments performed in triplicates, in B from two independent experiments in triplicates, and D is from one 
experiment in triplicates. CPZ concentrations are based on average of 1-3 different batches. All data are shown 





Figure 9A and B show results of WST-1 assay for MOLM13 and NRK, respectively. Empty 
PLGA and PLGA-PEG showed similar absorbance at across concentrations, but for MOLM13 
increasing somewhat with nanoparticle concentration. For CPZ-loaded PLGA and PLGA-PEG, 
the relative absorbance decreases with increasing CPZ concentration, with the MOLM13 
PLGA-PEG+CPZ sample showing a slight increase at the highest CPZ concentration, similar to 
what was seen for empty nanoparticles. It was noteworthy that the free CPZ showed only 
slightly improved cytotoxic effect towards MOLM13 cells compared to drug-loaded Figure 
9A), as was the case also for NRK cells (Figure 9B). 
 
After absorbance measurements, the cells were directly fixed in 2% formaldehyde in PBS 
containing Hoechst 33342, and examined using fluorescence microscopy (Figure 9C-D). 
Empty nanoparticles did not appear to affect cell death compared to control. The CPZ-
loaded nanoparticles showed similar death-inducing potency as free CPZ in both cell lines. 
Moreover, for both the WST-1 data and microscopic assessment of apoptosis, the NRK cells 
are less sensitive to CPZ in free or encapsulated form, compared to the MOLM13 cells. 
 
 
Figure 10 – Activity of blood platelet treated with empty and CPZ-loaded 
nanoparticles. Gel-filtered platelets were pre-incubated for 10 min with anti-P selectin 
and either free CPZ, empty or CPZ-loaded PLGA or PLGA-PEG nanoparticles. The cells 
were then incubated for 15 min with 20 µM thrombin receptor agonist peptide (TRAP) to 
activate the platelets and stimulate surface expression of P-selectin. Cells were then and 
analyzed for P-selectin externalization by flow cytometry. The data are from one 
experiment done with two parallels. Measurements were gated for fluorescent platelets 
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It has previously been shown that blood platelets are affected by CPZ [57]. Gel-filtered 
human blood platelets were pre-incubated for 10 min with either free CPZ or CPZ-loaded 
PLGA or PLGA-PEG nanoparticles, followed by 15 min incubation with 20 µM thrombin 
receptor agonist (TRAP) to stimulate activation (Figure 10). For free CPZ, there was a clear 
inhibition of thrombin-induced platelet activity, starting at around 180 µM. This was similar 
as CPZ-loaded PLGA-PEG nanoparticles, whereas the CPZ-loaded PLGA nanoparticles had a 
more potent inhibitory action. Empty nanoparticles of either variant, plotted against each 
their CPZ-loaded equivalent on X-axis, did not affect blood platelet activation at the 
concentrations tested. 
 
4.6 - Liposomal delivery studies of novel drug candidates 
To internalize the peptide-based N-acetyl-transferase (NAT) inhibitor, HEPC:CHOL film was 
hydrated with 2 mg/ml peptide in PBS and extruded. Spectroscopic analyses of fractions 
after gel filtration showed that the liposomes eluted in fraction 8, seen as a high base-line 
due to lipid content (Figure 11A). However, the majority of the peptide, identified with an 
absorption maximum at 260 nm, eluted in later fractions. Moreover, a distinct peak at 260 
nm was not seen on top of the baseline in fraction 8. Although no detectable amount of 
peptide was seen in the gel-filtered liposomes, it would be of interest to see if the minute 
amount present in the peptides could be sufficient to induce AML cell death. Since the 
peptide itself does not penetrate membranes, any effect could be ascribed to liposomes 
transporting the peptides into the cells. 
 
MOLM13 cells were treated with various V/V concentrations of unfiltered peptide-loaded 
liposomes, and samples taken after 24, 48 and 72 hours and fixed with buffered 2 % 
formaldehyde fix (pH 7.4) containing Hoechst 33342. The data from the microscopic 
evaluation of cell death is seen in Figure 11B. From this graph, no clear induction of 
apoptosis by the peptide-loaded liposomes is apparent. While the percentage of apoptotic 
cells was relatively high for all samples, including the controls, neither liposome dosage nor 
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Figure 11 – Loading efficiency of liposomes loaded with NAT-inhibiting peptides, and their effect on MOLM13 
cells. HEPC:CHOL (2:1 molar ratio) lipid thin film was hydrated with PBS containing 2 mg/ml NAT-inhibiting 
peptide, extruded and gel filtered on a Sephadex G50 medium size exclusion column. A: Fractions were collected 
and diluted in MQ water before analyses of peptide content at 260 nm by UV spectroscopy. B: MOLM13 cells 
were treated with various V/V concentrations of peptide-loaded liposomes, and samples taken and fixed with 
2% buffered formaldehyde added Hoechst 33342 and nuclear morphology used to determine presence of 




4.7 - Liposome-siRNA studies 
 
 
In addition to being drug carriers, liposomes can also be used to transport oligonucleotides 
like siRNA into cells [58]. To test if this could be done in AML cells, cationic liposomes, 





































Figure 12 – Transfection of HEK293 cells with GFP plasmid and GFP plasmid-targeting siRNA. Mean and 
median fluorescence of HEK293 cells (370 000 cells/ml) transfected with GFP plasmid using X-treme Gene 9 DNA 
Transfection Reagent, then treated with siRNA against GFP 24 hours later using Lipofectamine transfection 
reagent. Wash and resuspension in PBS or in 2% formaldehyde fix in PBS and flow cytometry done 72 hours 
after siRNA transfection. The graphs show mean (A) and median (B) fluorescence of cells without transfection 






As a proof of concept of the ability of siRNA to reduce expression of GFP, HEK293 cells were 
transfected with plasmids encoding for GFP, and after 24 hours, transfected with siRNA 
targeting GFP plasmid for silencing of GFP expression (0.02 µM). After 72 more hours, the 
fluorescence in the cells was analyzed by flow cytometry (Figure 12). Results were plotted 
for mean and median fluorescence (Figure 12A and B, respectively), which was then used as 
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Control Liposome siRNA Lipoplex 1 Lipoplex 2
Figure 13 – Flow cytometery results GFP-expressing MOLM13 cells incubated liposomes 
loaded with GFP-knockdown siRNA. MOLM13 cells (600 000 cells/ml) stably expressing GFP 
were incubated with empty cationic liposomes, free siRNA, or lipoplex for up to 72 hours. 
Samples were taken at given time points and were cells analyzed for fluorescence with an 
Accuri C6 flow cytometer, and data analyzed with the Accuri C6 software. Gating was done for 
living cells and on living cells expressing GFP. Graph A show the percentage of living cells that 
were fluorescent, while B shows the mean fluorescence of the fluorescent cell populations. The 
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ending experiment, one resuspended in PBS, and one resuspended in buffered 2 % 
formaldehyde fix. Control samples of either PBS or fix show virtually no fluorescence, looking 
at either mean or median. For both mean and median fluorescence, two trends are seen. 
The samples resuspended in 2 % fix show lower fluorescence values than their respective 
PBS samples, and siRNA-treated cells show lower fluorescence values slightly lower than 
their GFP-only-transfected counterparts. For the mean fluorescence (Figure 12A), where all 
GFP transfected cells have a mean fluorescence of around 6 000 000, the decrease is 
300 000 and 450 000 for PBS and 2% fix samples respectively, when looking at the addition 
of siRNA. The differences are more obvious when comparing median fluorescence values 
(Figure 12B), where the median fluorescence of the PBS samples go from 1 750 000 (GFP) to 
1 450 000 (siRNA), while the fix samples go from 1 300 000 (GFP) to 1 000 000 (siRNA). 
 
Lipoplex cationic produced from cationic liposomes and GFP silencing siRNA was tested on 
MOLM13 cells expressing GFP. The cells were incubated for up to 72 hours with either 
empty liposomes, free siRNA (0.42 µM), or lipoplex (no. 1: 0.42 µM; no. 2: 0.14 µM). Samples 
were taken every 24 hours and measured directly with flow cytometer. With gating for the 
GFP fluorescent cell population, the graphs show percentage of all cells with fluorescence 
(debris excluded) (Figure 13A), and mean fluorescence of fluorescent cell population (Figure 
13B), plotted based on time after original treatment. 
 
Figure 13A shows that there was no apparent change in the percentage of GFP-positive cells 
in the samples treated with siRNA loaded liposomes, at any of the time point investigated. 
The percentage varying between 62 % and 66 % for all samples, indicating no effect on the 
ratio of cells with GFP expression from either treatment or incubation time. From Figure 
13B, the mean fluorescence increases with treatment time for all treatments. From these 
analyses, there seems also to be little negative effect of GFP-expression from the siRNA 
loaded liposomes. From the higher mean fluorescence and no change in percentage of 
fluorescent cells, longer incubation time would seem to indicate an increase in GFP 





5.1 - Nanocarrier characterization: Size and morphology 
This study wanted to evaluate whether nanocarriers could have potential as delivery 
systems for anti-AML therapy. The first obstacle for any drug carrier is its physico-chemical 
properties, where size being perhaps the most crucial feature besides biocompatibility. The 
nanocarriers used in this study were liposomes and PLGA based nanoparticles, both systems 
with low impact on biological processes [59, 60]. As for size, both the PEGylated and cationic 
liposomes had acceptable size, with PEGylated liposomes being smaller than the cationic 
(Figure 1A-B and Table 1), despite the fact that both liposome types were passed through 
the same 100 nm filter. However, the TEM images revealed that the PEGylated liposomes 
showed more defined and intact structure while cationic liposomes appeared more irregular 
in shape and overall more unstable (Figure 2). These differences can be attributed to the 
stabilizing steric effect of PEG polymer, preventing agglomeration, though other factors such 
as lipid composition and charge may influence. PEGylated liposomes were for example made 
with PC, while cationic with HEPC and the positively charged DOTAP. While the 
morphometric analysis of cationic liposomes proved difficult due to aforementioned 
reasons, TEM does provide good insight into structure, and both TEM and DLS showed good 
overlap in results, with both showing favorable single peak size distributions with low SD, 
and cationic showing the same relative increase in size compared to PEGylated for each 
method. 
 
The same agreement between DLS and TEM was however not found with PLGA 
nanoparticles. While TEM and morphometry showed that CPZ-loaded PLGA and PGLA-PEG 
nanoparticles as having diameters of mostly single peak around 100-200 nm, with some 
larger particles around 500-600 nm (Figure 3), DLS displayed a much larger size and size 
variance for both, with multiple peaks along 100-1000 nm range and z-average and peak size 
around 400 nm (Figure 1C-D and Table 1). The lower TEM mean diameter could be to the 
staining process, e.g. shrinkage during drying, as well as large nanoparticles not binding to 
the TEM grid, and being washed away. The reason could also be due to DLS results coming 
from the intensity measurement of each nanoparticle, with larger particles resulting in 
higher intensity and skewing the results and peaks towards higher size values. Though it is 
43 
standard to look at intensity, having the DLS measure nanoparticle volume instead of 
intensity would perhaps give more representative results. 
 
Finally, DLS will not be able to distinguish between large particles and aggregates, whereas 
these can easily be separated from each other by TEM. The nanoparticles were several times 
spun down into pellets and resuspended by pipetting during production, which could result 
in aggregation. The question is whether the DLS is measuring single particles or 
agglomerates, and if TEM images show single particles in close contact or agglomerates. For 
TEM morphometry, the former is assumed, while for DLS, the latter appears to be the case. 
Looking at the difference between PLGA and PLGA-PEG from TEM and DLS, neither size, size 
distribution nor shape seems to be among them, with similar values across the board (Table 
1). The only difference is seen in the TEM images, where PLGA show much more staining 
medium around and between nanoparticles, while PLGA-PEG appear more clearly defined 
(Figure 3). As TEM was only performed once, it is uncertain whether the difference arose 
due to inconsistent staining, or differences in polymer composition and CPZ loading. 
 
Overall, the produced liposomes and nanoparticles all feature favorable size characteristics 
based on their intended purpose. Despite nanoparticles having larger diameter, all produced 
nanoparticles were in the size range where they can pass freely through blood. While they 
may be size excluded from certain endocytic pathways, they are still in particle size range 
where they can be taken up by the cell through either phagocytosis and micropinocytosis 
[37, 61, 62]. Though the nanoparticles show larger variance in size distribution and presence 
of large particles, this can be amended by filtration. It was however noted that heating at 37 
°C and mixing the nanoparticles resulted in significant aggregation after already 24 hours, 
and much more so for CPZ-loaded nanoparticles (data not shown). For nanoparticles stored 
cold (4 °C), and to a lesser degree empty nanoparticles, only minor increases in Z-average 
was noted during up 72 hours of storage. While the agglomeration may not have affected 
the release rate experiment, it definitely an issue when considering injection into the 
bloodstream, and should be studied further. 
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5.2 - Drug encapsulation into nanocarriers 
The next obvious requirement for a therapeutic nanocarrier is its ability to carry sufficient 
amounts of drugs. With the PLGA and PLGA-PEG nanoparticles, a drug loading of 3.3 % for 
PLGA and 5.3 % for PLGA-PEG was obtained, with an encapsulation efficiency of 20% for 
PLGA and 30% for PLGA-PEG (Table 2). This is lower than was reported by Halayqa et al. [56], 
but still sufficient to produce AML cell death with equal capacity as the free drug. However, 
while Halayqa et al. found a rapid release rate, where 80% of the drug was released within 5-
12 hours depending on formulation, the nanoparticles in the present study retained the drug 
during the whole experiment, 72 hours (Figure 4). A noteworthy observation was that while 
the PLGA-PEG nanoparticles had a higher drug loading, they had a poorer ability to retain the 
drug during the release experiment. In fact, the PLGA-PEG nanoparticles very quickly 
released CPZ, so much that after 10 hours, the CPZ concentration in PLGA-PEG nanoparticles 
was below that of PLGA. After this point, the CPZ concentration remained stable for PLGA-
PEG, while it for PLGA remained stable throughout the experiment, except for a minor 
release during the first 120 minutes. These results may be explained by weak interactions 
between CPZ and PEG located both outside and inside the particle. Such interactions can 
explain the rapid release, and why after some time, the CPZ concentration of PLGA-PEG 
better reflects the amount of PLGA polymer in the particle relative to PLGA nanoparticles. It 
would be interesting with further studies to compare PLGA polymer ratios between different 
types of PLGA nanoparticles, and ratio of their CPZ loading capacity. Moreover, since CPZ has 
a protein binding of about 90% in blood [63], the role of proteins in the drug release of 
nanocarriers should be investigated. 
 
This quick release can be an issue for nanocarrier-mediated drug delivery, particularly with 
CPZ, where leaky nanoparticles would contribute to unwanted side effects from unintended 
expose of CPZ, to the central nervous system. Thus for this particular formulation against 
AML cells, it is preferable with minimal leakage. The release rate of PLGA-PEG is also to quick 
compared to the 30 hours CPZ half-life in blood [63]. Inclusion of PEG is however still 
desired, but would have to be included through some other method, perhaps after forming 
the PLGA nanoparticle, in order to provide the benefits of PEG, while maintaining stable drug 
loading and circumventing the issue of leakage. 
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A point to note about the experiment setup of mixing the nanoparticles before HPLC 
analysis, is while the total CPZ concentration remained the same for PLGA from start and 
end, loss of total CPZ was noted for PLGA-PEG. While a decrease in pellet CPZ concentration 
coincided with increase in supernatant concentration, and the time range for stable 
concentration was the same for both, the total start concentration was higher than end 
concentration. This seeming disappearance of CPZ was likely due to some CPZ drying along 
walls of glass container when shaking. This was particularly evident when attempting the 
experiment using plastic containers (Supplementary Figure 2), with white rings appearing 
along the side of the container, coming from nanoparticles, CPZ, or both. Future studies, 
aiming for more accurate CPZ concentrations and nanoparticle-drug behavior would benefit 
from not only using closed glass containers, but also ensuring proper mixing. 
 
Contrary to CPZ, a very limited drug loading into liposomes was achieved with the peptide-
based NAT inhibitors, below the detection limit for spectrophotometric analyses (Figure 
11A). While external peptide was detected in later gel filtration fractions, fractions 
containing liposomes showed no characteristic peptide peak, indicating either very low 
encapsulation or none at all. For this particular drug candidate, another approach to 
nanonization must be developed. 
 
5.3 - Nanocarrier internalization into AML cells 
A drug carrier can either release the drug in the blood stream in a controlled manner, deliver 
the drug locally at the site of the disease, for instance in the tumor, or be engulfed by the 
tumor cells. For anti-cancer therapy, the latter is preferred to minimize toxic side effects 
from the cytostatic drug. Both the liposomes and the PLGA-based nanoparticles were 
internalized into AML cells (Figure 5-Figure 7). 
 
The tests on AML blasts from a patient were analyzed by two different gating strategies. 
Either by the percentage of cells above a fluorescence limit, based on autofluorescence of 
control cells, or by looking at the mean fluorescence intensity (MFI) of the whole population 
(Figure 5). The first strategy showed higher percentage of fluorescent cells for higher 
liposome concentration, with a linear relation between the two. The issue with this strategy 
however was the relatively low fluorescence intensity of the nanocarriers resulting in small 
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increases in MFI relative to control. Data from the former method takes into account 
fluorescence increase of all cells, not just gated, and give a better representation of liposome 
uptake. This strategy also resulted in a linear relation between dose and intensity, in this 
case from MFI, and liposome dosage, but with less variance at highest concentration, 
indicating more reliable data between parallels for this gating strategy. Note that for patient 
cells however, gating was also done to exclude outlier cases. It is not quite clear what these 
events were, or what their actual fluorescence was, as they mostly had either maximum or 
minimum fluorescence intensity.  
 
More thorough uptake studies were performed using PEGylated liposomes on MOLM13 and 
MV4-11 AML cell lines, and PLGA and PLGA-PEG on MOLM13, with testing for both dose- 
and time-dependent uptake. For liposomes, a linear increase for both cell types and all 
experiments, indicating not having reached endocytic saturation for liposomes through 
neither liposome concentration nor incubation time (Figure 6).  Estimation of a saturation 
point for liposomes would require further studies with either higher liposome 
concentrations or longer incubation times. Both cell types displayed similar uptake behavior 
for time-experiment, starting at same MFI, but with MOLM13 reaching 50 % higher MFI after 
3 hours, indicating more rapid uptake ability. For dose experiments, the liposomes displayed 
very similar uptake behavior. 
 
The confocal images clearly show the presence of fluorescence inside cells with both 
liposomes (Figure 6) and PLGA-based nanoparticles (Figure 7). Additionally, the fluorescence 
is not homogenously distributed within cells, but also appears as spots along the periphery 
of cell. The latter is particularly noticeable for MOLM13 cells. For liposomes, the 
fluorochrome was conjugated to phosphatidyletanolamine, a phospholipid known to not be 
transferred between membranes (G. Barratt, Institut Galien, Univeristé Paris 11-sud, Pers. 
Comm. 2015), thus is the internalization of fluorescence in fact uptake of liposomes. To 
further prove this, liposomes were loaded with another green fluorochrome inside the 
aqueous phase, and made with red fluorochrome -tagged lipids. With two different colors 
and fluorochrome types, confocal imaging would shed more light on the intracellular fate of 
liposomes, with intact liposomes showing up as yellow, or as green and red fluorescence if 
broken. The experiment was however unsuccessful, with inconclusive results showing no 
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fluorescence at all under the confocal microscope, most likely due to issues with production 
and imaging settings. 
 
Compared to liposomes, PLGA and PLGA-PEG displayed much stronger MFI readings with 
flow cytometer, with PLGA-PEG around twice as strong as PLGA for dose and time 
experiments (Figure 7). This difference can be explained by the formulations being different, 
with different nanocarrier types and fluorochrome, resulting in nanoparticles containing 
higher Nile Red (NR) fluorochrome concentration than liposomes, and/or the fluorochrome 
giving stronger fluorescence signal. While PLGA dose experiment shows linear increase in 
MFI as with liposomes, indicating no saturation, the dose experiment for PLGA-PEG show 
higher MFI than PLGA, and looks as if it is reaching saturation based on curve adaptation. 
This is also supported by the confocal microscopy of these experiments, with stronger 
fluorescence for PLGA-PEG. For the time experiment, nanoparticles were incubated for 6 
hours instead of 3 as with liposomes, and the curves demonstrate an increase in MFI with 
longer incubation time. The results also show signs of reaching uptake saturation, and at 
similar levels for both nanoparticle formulations. Note that the concentration of each 
nanoparticle batch will differ, and as a result affect the readings. Also worth noting is that 
the PLGA and PLGA-PEG were made with same amount of the NR fluorochrome, but that 
similar loading, and thus fluorescence readings, are not guaranteed, as demonstrated with 
CPZ loading experiments (Table 2). 
 
The nanoparticles show, as with liposomes, fluorescence clearly inside cells, with points 
throughout the cells with higher fluorescence intensity (Figure 6). This alone does not 
however demonstrate nanoparticle internalization, which is the purpose of the experiment. 
NR is intercalated with the nanoparticles, not conjugated to the polymers, and could be 
released in a similar manner as CPZ (Figure 4). However, the work of Xu et al. showed very 
limited release of NR from PLGA nanoparticles [64], and this, along with the spotted 
distribution of fluorescence in the cells suggest that the increase in fluorescence is indeed 
due to nanoparticle internalization.  
 
As it would be pertinent to better understand uptake mechanisms and uptake path for 
nanocarriers and AML cells, uptake inhibition studies were done on MOLM13 with 
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fluorescent liposomes. For this project, chemical inhibition experiments were performed 
using chlorpromazine (CPZ) and dynasore hydrate (DH) to inhibit clathrin-mediated 
endocytosis, and genistein (GS) to inhibit caveolin-mediated endocytosis. Filipin complex 
(FC) was also tested as a caveolin-inhibitor, but as the results were not comparable or usable 
due to high cell death, the data were not included. 
 
For both CPZ and GS, no clear trend was demonstrated with increased inhibitor 
concentration (Figure 8A). DH on the other hand seemed to enhance uptake (Figure 8A), 
contrary to expectations, but only at minor levels. Incubating the cells with increased 
concentrations of liposome did not reveal any uptake inhibition (Figure 8B). A slight shift 
down in MFI is noted for DMSO samples at higher concentrations, though this is likely due to 
poor cell health brought on by too high DMSO concentrations. These experiments thus 
suggest that liposomes were taken up through clathrin- or caveolin-independent 
endocytosis, or that a compensatory mechanism is triggered if one of the events is inhibited. 
Confocal microscopy (data not included) showed liposomes clearly inside the cells, and not 
for example bound to the cell membrane surface. Given the liposome size and cell type, it 
would not be amiss to suggest phagocytosis or macropinocytosis as the mechanisms of 
uptake, based on available information [37, 61, 62]. 
 
For a more thorough inquiry into the liposome uptake pathways, further studies could 
include more inhibitors covering several mechanisms of endocytosis simultaneously, and 
increased incubation times to see if inhibitors require more time to activate. Control studies 
should also be included, using probes or agents designed against specific pathways, so as to 
ensure that pathway inhibition is actually achieved.  
 
5.4 - Nanocarrier cytotoxicity 
With nanocarrier production, drug loading, and cell internalization achieved, the next logical 
step is to test nanocarriers for cytotoxic drug delivery against AML cells. Both CPZ loaded 
PLGA and PLGA-PEG nanoparticles, as well as free CPZ, induced MOLM13 cell death with 
similar potency, while neither PLGA nor PLGA-PEG induced any cell death when empty 
(Figure 9). Empty nanoparticles did however have an effect on the readings for WST-1 
measurements, contributing to increased absorbance with increased concentrations, and 
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thus seemingly increasing metabolic activity or cell division. This could be ascribed to the 
nanoparticles themselves absorbing the light, as fluorescence microscopy showed no such 
trend and 100 % cell death for higher concentrations of CPZ-loaded nanoparticles (Figure 9C-
D). This is further supported when noting that the increase in empty nanoparticle 
absorbance relative to control is similar to that of the increase in CPZ-loaded nanoparticles 
compared to free CPZ. While controls were included to compensate, higher concentrations 
still showed a shift up in absorbance. Why this was only noticed for MOLM13 and not NRK 
lies with NRK showing much higher absolute absorbance values overall compared to 
MOLM13 (not shown), thus minimizing the nanoparticle contribution to absorbance. 
 
Although metabolic assays like WST-1 are considered a reliable measurement of cytotoxicity 
and cell death, fluorescence microscopy was performed in tandem to verify the results. With 
microscopy, individual cells were imaged and counted for apoptosis (Supplementary Figure 
1), granting a much more direct measurement of cell death. The results obtained by 
microscopy corresponded well with the WST-1 data, with higher CPZ concentration 
treatments showing 100 % cell death (Figure 9). Note that the microscopy shows much 
quicker change in cell death. This difference can be explained by early pre-apoptotic cells 
having normal nuclear morphology, but likely having reduced metabolism, and pure 
apoptotic cells still having some metabolism. Trends to note from this experiment are that 
MOLM13 cells are more sensitive to CPZ loaded PLGA and PLGA-PEG nanoparticles than 
NRK, based on the lower CPZ concentrations and smaller range of concentrations that cover 
0-100% cell death. This gives a beneficial therapeutic index (TI), requiring relatively high drug 
concentrations to achieve toxic side effects, while at the same time low concentrations for 
therapeutic effect. The next trend is that nanoparticles induce a similar level of cell death as 
CPZ based on CPZ concentrations. Not only does this suggest successful drug internalization, 
as leaked CPZ would not account for such an effect given the amount in supernatant (Figure 
4 and Table 2), but it also suggests that difference between MOLM13 and NRK is not a result 
of a difference in nanoparticle uptake. Finally, the data suggests that the targets of CPZ in 
MOLM13 cells are intracellular. If the targets were membrane receptors, a rapid and near 




Blood platelets are of particular concern in AML therapy, due to their proximity to the 
nanocarrier target, and their already compromised state and reduced numbers for AML 
patients, brought on by the unregulated cell proliferation of cancerous cells. Free CPZ and 
CPZ-loaded PLGA-PEG showed inhibitory effect with similar potency towards platelet 
activation by TRAP, whereas CPZ-loaded PLGA had a more powerful inhibitory action (Figure 
10). This could not be ascribed to the PLGA alone, since empty PLGA or PLGA-PEG 
nanoparticles had no negative impact on platelet activation. Apparently, PLGA is able to 
present CPZ more efficiently to the platelets, either by associating to the membrane, or by 
internalization. The process of PEGylating the PLGA nanoparticles would seem even more 
beneficial based on these findings, as it will reduce nanoparticle inhibition of platelets, and 
thus reduce harmful toxic effect and increase the therapeutic window. The higher the 
tolerance for any misdirected nanoparticles and CPZ leakage, the better. Given the nature of 
AML and effect CPZ-loaded nanoparticles, it would be prudent to perform similar 
experiments with blood constituents such as other leukocytes and bone marrow stem cells. 
Different cell types may exhibit different uptake behavior and CPZ sensitivity, and in turn 
affect the overall tolerance of CPZ. 
 
Contrary to the CPZ-loaded nanoparticles, the liposomes loaded with NAT-inhibiting peptide 
showed no cytotoxic activity towards MOLM13 cells (Figure 11B). The overall high cell death 
noted for every sample is likely due to unhealthy cells, as it also seen for control. The lack of 
cytotoxic results is not surprising considering the poor loading of the peptide in the 
liposomes (Figure 11A). In addition, it is also uncertain what the intracellular fate of 
liposomes is, and whether the peptide survives after internalization and reaches its target 
site. Still, it is possible that the peptide resulted in growth inhibition, but not cell death, 
which would have been detected by metabolic assays like the WST-1 assay. 
 
Another drug-loaded liposome experiment was performed with MOLM13 and MV4-11, 
treated with either empty liposomes or with liposomes loaded with the 6BrCaQ HSP90-
inhibitor (Supplementary Figure 4). This experiment gave generally poor results, probably 
due to low cell density for certain samples and bacterial infections. Most notable however is 
the fact the results point to “empty” liposomes being more cytotoxic for both cell types. This 
is most likely explained by a mix up between the empty and the loaded liposomes. However, 
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even the “loaded” liposomes demonstrated high cell death at high enough concentrations. 
This goes against the findings of Dr. Félix Sauvage and Prof. Lars Herfindal, whose 
experiments showed a clear dose dependent apoptotic effect of 6BrCaQ in liposomal 
suspension on MOLM13 cells after 24 hours (Supplementary Figure 3). 
 
5.5 - Liposomal delivery of siRNA for RNAi-based silencing of GFP expression 
To investigate a more advanced strategy of targeted therapy using nanocarriers, studies 
were done with cationic liposomes for their suitability as siRNA delivery vehicles for the 
induction RNA interference (RNAi) and gene knockdown. This method is appealing as it 
allows for using siRNA designed to only target genes that are either specific or important for 
cancer, thus avoiding off-target effects in a way that cytotoxic drugs cannot. 
 
Testing siRNA against GPF plasmid as a proof-of-concept showed promise, with successful 
plasmid and siRNA transfection of HEK293 cells (Figure 12). While the difference is small, the 
cells showed a decrease in GFP MFI when treated with siRNA, indicating successful 
internalization of siRNA into the cytosol and RNAi. Although the reductions appears minor, 
the long half-life of GFP in cells (about 26 h) makes the silencing of GFP a particularly difficult 
task [65]. The silencing must be effective and sustained for a long period of time, and as 
such, a different probe would be preferable for future studies. 
 
Samples that were fixed before analysis showed lower fluorescence intensity than living 
cells. This could be due to leakage of GFP from the permeabilized cell membrane, causing a 
lowered concentration of GFP and thus fluorescence (M. Enger, Department of Clinical 
Science, University of Bergen, pers comm. 2015). Both of these findings, siRNA effect and 
fixation effect, are also made clearer when looking at median fluorescence values, as 
opposed to mean fluorescence intensity (Figure 12). 
 
Following this, a study was then done using cationic liposomes for siRNA delivery, and to 
MOLM13 cells stably expressing GFP. While the small differences in MFI between the 
treatments are of a similar degree as the HEK293 experiment, no trend or siRNA effect was 
observed (Figure 13B). Note that this is despite being treated for as long as HEK293, and with 
higher siRNA concentrations. As a result of this, this particular experiment and experimental 
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setup offers no conclusion on the ability of siRNA against GFP expression in MOLM13 cells. 
Not only was no gene silencing observed, the MFI increased with incubation time, likely due 
to continued GFP expression, as the percentage of cells with GFP expression remaining more 
or less same for all treatments and time points (Figure 13A). 
 
Given the use of cationic liposomes, instead of simply Lipofectamine as with previous 
experiment, one would assume a stronger effect from siRNA due to better loading brought 
on by the electrostatic interaction between siRNA and cationic DOTAP lipids. Another issue 
could be internalization, which was only demonstrated with neutral/PEGylated liposomes, or 
the currently uncertain intracellular fate of liposomes and possible lysosomal degradation of 
the oligonucleotide. A common challenge of using siRNA itself, is that it may very well have 
been degraded by RNase at some point during the production and experiment. While some 
siRNA may diffuse into liposomes, most of it will remain outside, and consequently would 
benefit from encapsulation. Moreover, enhanced cellular uptake using liposomes 
functionalized with folate as this is associated with clathrin-mediated endocytosis [66]. The 
use of targeting ligands to enhance GFP silencing has proven successful in other cell systems 




6. Concluding remarks 
The present study has investigated some crucial aspects of nanocarriers to be fulfilled in 
order to be successful as drug delivery systems. Although some data were inconclusive, or 
even in disfavor of nanocarriers, the overall impression is that nanocarriers have a great 
potential in AML therapy. 
 
The best candidate proved to be nanoparticles based on the PLGA polymer. These had 
acceptable size, drug loading and cytotoxicity towards AML cells. In addition, the effect on 
normal cell systems like NRK cells and blood platelets equaled that of the free drug. The 
main purpose of the nanocarriers in this aspect was to prevent CPZ from crossing the blood-
brain barrier (BBB). This must be confirmed, either by in vitro models of the BBB, or in 
mouse studies. Moreover, a superior drug retention in the nanoparticles was obtained using 
PLGA without PEG. But these nanoparticles had negative impact on blood platelets, and a 
method of post-insertion of PEG onto the PLGA nanoparticles must be established. Finally, 
the nanoparticles must be tested for efficacy in AML-transplanted animals. Since the 
nanoparticles could be loaded with a fluorescent dye, they can be followed by in vivo 
imaging, and monitored for biodistribution as well as anti AML activity. A last effort to 
enhance the AML specificity will be to add a targeting ligand to the nanoparticles in order for 
them to be selectively taken up by AML cells. 
 
Although the produced liposomes showed better size and morphology, they were not 
suitable as drug delivery systems for the highly water-soluble peptide-based drug. Not only 
was the drug loading very inefficient, but no cytotoxicity was observed. One can question 
whether the drug is suitable for liposomal delivery at all, or if other systems might prove 
better, such as different porous nanoparticles, or dendromers. However, the first priority 
must be to prove the drug efficacy intracellularly, e.g. by microinjection. 
 
Another liposomal formulation, namely lipoplexes carrying siRNA also failed to give the 
desired effect. The successful downregulation of proteins like GFP has been demonstrated 
by others, and the high capacity of AML cells to internalize liposomes suggests that this has 
potential in AML cells as well. However, the lack of a targeting ligand, as well as uneven 
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appearance on TEM images, can explain the failure to silence GFP in the present 
experiments. Here, optimization of both lipoplex production and composition, as well as 
experimental conditions, can improve the results. 
 
It appears that nano-sized drug delivery systems indeed have a potential for anti-AML 
therapy, although not for all systems, and all drugs. Particularly encouraging was the findings 
on the re-purposing of CPZ, which is a well-documented drug, and will need less 
documentation before reaching clinical trials. The combination of re-purposing of drugs and 
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Supplementary Figure 1 – Assessment of cytotoxicity by fluorescent microscopy of cells stained with the DNA 
dye Hoechst33342. The images show cells after fixation in 2% buffered formaldehyde added 10μg/ml 
Hoechst33342 as they appear under the microscope using a DAPI filter. A: Cells added 1% PBS in the medium 
(control). B: Cells added CPZ to 15μM. C: Cells added empty PLGA-PEG NPs at 2.5%, D: Cells added CPZ-loaded 
PLGA-PEG NPs at 1.3%, corresponding to 12μM. Note that while the control and empty PLGA-PEG NP-treated 































PLGA pellet PLGA-PEG pellet
PLGA supernatant PLGA-PEG supernatant
Supplementary Figure 2 – Drug encapsulation and release of CPZ-loaded PLGA and PLGA-PEG nanoparticles. 
CPZ-loaded nanoparticles were left to stir in PBS (pH 7.4) at 37 °C in plastic vials at 650 RPM. At the given time-
points, samples were taken and analyzed for CPZ-content by HPLC analysis as described in the Methods 
section. The data shows chlorpromazine concentration of nanoparticle pellet (P), resuspended in original 
sample outtake volume, and supernatant (S) of PLGA and PLGA-PEG nanoparticles from one experiment. 
Supplementary Figure 3 – HSP90-inhibitor loaded liposomes. The 
figure shows that 6BrCaQ-loaded liposomes induce MOLM13 cell 
death after 24 h of incubation. The experiment was performed by Dr. 
Félix Sauvage (Institut Galien, Fac. de Pharmacie, Univ. Paris 11-sud, 
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Supplementary Figure 4 – Cell death of MOLM13 and MV4-11 cells treated with various concentrations of 
empty and HSP90-inhibitor loaded liposomes. AML cell were treated with various concentrations of empty or 
6BrCaQ-loaded liposomes, and samples taken at the given time-points, fixed in 2% buffered formaldehyde with 
the DNA stain Hoechst 33342. The percentage of apoptotic cells was determined by fluorescent microscopy. The 
data are from one experiment. 
